About Me
After completing my high school education at Ankara Science High School (Ankara Fen Lisesi), I began my medical education at Ankara University Faculty of Medicine and graduated in 2013. Following graduation, I worked briefly as a general practitioner. Between 2013 and 2018, I completed my Internal Medicine residency at Hacettepe University Faculty of Medicine, Department of Internal Medicine, during which I was actively involved in both clinical practice and academic research.
Between 2018 and 2021, I completed my Medical Oncology fellowship at Ankara University Faculty of Medicine, Division of Medical Oncology. During my fellowship, I gained extensive clinical experience across all core areas of Medical Oncology, particularly in the systemic treatment of solid tumors, immunotherapy, and targeted therapies. In addition, I took doctoral-level courses in statistics, immunopathology, and basic oncology laboratory techniques.
From 2021 to 2023, I worked as a Medical Oncologist at two of Turkey’s leading oncology centers: Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital and Etlik City Hospital. During this period, I assumed active clinical responsibilities in the systemic treatment of genitourinary cancers in particular, as well as gastrointestinal, breast, and other solid tumors. I also contributed to the conduct of multicenter national studies based on real-world data.
Between 2023 and 2025, I served as a postdoctoral researcher at the Dana-Farber Cancer Institute and Harvard Medical School. In this role, I participated in translational and clinical research projects across various cancer types, with a primary focus on urogenital cancers. I contributed to international multicenter studies investigating treatment response and toxicity biomarkers through the integration of genomic, transcriptomic, and clinical data. I took active responsibility in projects involving antibody–drug conjugates, predictors of immunotherapy response and toxicity, and real-world evidence.
Following my return to Türkiye, I am currently working as a faculty member in the Division of Medical Oncology at Ankara University Faculty of Medicine. My responsibilities include the management of outpatient and inpatient clinics, undergraduate and postgraduate teaching activities, training of residents and subspecialty fellows, and coordination of clinical research. I also serve as a principal investigator and sub-investigator in phase I–II–III clinical trials.
My scientific work includes original research articles, systematic reviews, meta-analyses, and book chapters published in international peer-reviewed journals. My studies have been presented as oral presentations and poster abstracts at international conferences such as the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO), and the ASCO Genitourinary Cancers Symposium (ASCO GU). I serve as a peer reviewer for numerous national and international journals and continue my role as a member of editorial boards, particularly for leading oncology journals such as The Oncologist.
In addition to my academic activities, I have participated in national and international courses, preceptorship programs, and clinical research training programs as part of my professional development. I am a member of the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO), and other national and international scientific societies.
Education
| Year | Education | Institution |
|---|---|---|
| 2018–2021 | Medical Oncology Subspecialty Training | Ankara University Faculty of Medicine |
| 2013–2018 | Internal Medicine Residency | Hacettepe University Faculty of Medicine |
| 2007–2013 | Medical Degree (MD) | Ankara University Faculty of Medicine |
| – | High School Education | Ankara Science High School |
Scientific Society Memberships
| Year | Organization Name | Role |
|---|---|---|
| 2016 | American Society of Clinical Oncology (ASCO) | Member |
| 2018 | European Society for Medical Oncology (ESMO) | Member |
| 2018 | Turkish Society of Medical Oncology | Member |
| 2021 | Society for Immunotherapy of Cancer (SITC) | Member |
| 2023 | European Organisation for Research and Treatment of Cancer (EORTC) | Member |
| 2025 | Oncology Group Association | Member |
Scientific Awards
| Year | Award | Organizing Institution / Conference |
|---|---|---|
| 2025 | Merit Award | American Society of Clinical Oncology (ASCO), ASCO Genitourinary Cancers Symposium |
| 2023 | Best Oral Presentation Award | 15th European Multidisciplinary Congress on Urological Cancers (EMUC23), ESMO – ESTRO – EAU |
| 2022 | Oral Presentation Award (Third Place) | 6th National Immunotherapy and Oncology Congress |
| 2022 | Best Oral Presentation Award | 12th National Haseki Congress |
| 2022 | Best Oral Presentation Award | Turkish Society of Medical Oncology Congress |
| 2021 | Abstract Award (Third Place) | Turkish Society of Medical Oncology Congress |
| 2020 | Best Oral Presentation Award | Turkish Society of Medical Oncology Congress |
Publications
| Publication | Authors | Journal |
|---|---|---|
| Comorbidity burden and effectiveness of immunotherapy in metastatic renal cell carcinoma | Yekedüz E, Zarba M, Saad E, Chehade REH, Eid M, Saliby RM, Steiner C, Machaalani M, Nawfal R, Semaan K, Ürün Y, Heng DYC, Choueiri TK. | Clinical Genitourinary Cancer 2025 |
| Impact of prostate radiotherapy on survival outcomes in patients with metastatic castration-sensitive prostate cancer: A meta-analysis of randomized phase 3 clinical trials | Yazgan SC, Yekeduz E, Sayan M, Ravi P, Bolek H, McKay RR, Akyurek S, Boeve LMS, Bossi A, James ND, Fizazi K, Gillessen S, Choueiri TK, Urun Y. | Eur Urol Oncol 2025 |
| Impact of comorbidity on survival in cancer patients receiving immune checkpoint inhibitors | Yalciner M, Yazgan SC, Mocan EE, Karaoglan BB, Bolek H, Yekeduz E, Urun Y. | Clin Transl Oncol 2025 |
| Comparison of two alternative sequences with cabazitaxel and 177lu-psma-617 in metastatic castration-resistant prostate cancer: A retrospective multicenter study (lucas) | Bolek H, Yazgan SC, Ceylan F, Esteban-Villarrubia J, Arslan C, Kus T, Tural D, Sendur MAN, Kucuk NO, Cingi Ozdemir E, Castro E, Yekeduz E, Urun Y. | Eur J Cancer 2025;217(115226. |
| Sunitinib in metastatic renal cell carcinoma: Clinical outcomes across risk groups in a turkish oncology group kidney cancer consortium | Bolek H, Kuzu OF, Sertesen Camoz E, Sim S, Sekmek S, Karakas H, Isik S, Guliyev M, Akkus AF, Tural D, Arslan C, Goksu SS, Sever ON, Karadurmus N, Karacin C, Sendur MAN, Yekeduz E, Urun Y. | Cancer Commun (Lond) 2025;45(5):572-6. |
| Navigating second-line therapy in metastatic renal cell carcinoma: A comparative analysis of immune checkpoint inhibitors and tyrosine kinase inhibitors: A study of turkish oncology group kidney cancer consortium | Aykan MB, Bolek H, Yekeduz E, Sertesen E, Tural D, Karacin C, Sendur MAN, Ucar G, Arslan C, Isik S, Sim S, Sever ON, Hacioglu B, Sezgin Goksu S, Ozguroglu M, Karadurmus N, Urun Y. | Ther Adv Med Oncol 2025;17(17588359251331540. |
| Sodium-glucose cotransporter 2 (sglt2) as a potential biomarker and target in papillary renal cell carcinoma | Akkus E, Yekeduz E, Urun Y. | Clin Genitourin Cancer 2025;23(2):102314. |
| Evaluating the prognostic role of glucose-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors in first line: A study by the turkish oncology group kidney cancer consortium (tkcc) | Bolek H, Kuzu OF, Sertesen Camoz E, Sim S, Sekmek S, Karakas H, Isik S, Gunaltili M, Akkus AF, Tural D, Arslan C, Goksu SS, Sever ON, Karadurmus N, Karacin C, Sendur MAN, Yekeduz E, Urun Y. | Clin Transl Oncol 2025 |
| Treatment Patterns and Attrition in Metastatic Renal Cell Carcinoma: Real-Life Experience from the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database | Bölek H, Sertesen E, Kuzu OF, Tural D, Sim S, Nahit Şendur MA, Uçar G, Işık S, Hacıoğlu B, Çiçin İ, Arslan Ç, Göksu SS, Nuray Sever Ö, Karaçin C, Karadurmuş N, Özgüroğlu M, Yekedüz E, Ürün Y. | Clinical Genitourinary Cancer.2024. |
| The Prognostic Value of Elimination Rate Constant K Score of Prostate-Specific Antigen in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Docetaxel | Yazgan SC, Sarı A, Bölek H, Yekedüz E, Ürün Y. | Prostate International. 2024. |
| Androgen receptor pathway inhibitors and drug-drug interactions in prostate cancer | Bolek H, Yazgan SC, Yekeduz E, Kaymakcalan MD, McKay RR, Gillessen S, Urun Y. | ESMO Open. 2024;9(11):103736. |
| Effectiveness of androgen receptor pathway inhibitors and proton pump inhibitors | Yazgan SC, Yekeduz E, Urun Y. | Prostate. 2024. |
| Combination therapies in patients with favorable risk metastatic renal cell Carcinoma: A Systematic Review and Meta-Analysis | Bolek H, Yekeduz E, Urun Y. | Cancer Treat Rev. 2024;122:102667. |
| Thromboembolic risk in prostate cancer patients treated with PARP inhibitors: A systematic review and meta-analysis | Yazgan SC, Akkus E, Yekeduz E, Urun Y. | Crit Rev Oncol Hematol. 2024;198:104376. |
| Meta-analysis of platinum chemotherapy combinations with immunotherapy in metastatic urothelial carcinoma | Bolek H, Yazgan SC, Yekeduz E, Urun Y. | Oncologist. 2024. |
| The prognostic role of pan-immune inflammation value in patients with metastatic castration resistance prostate cancer treated with Lutetium-177 ((177)Lu)-PSMA-617 | Yazgan SC, Yekeduz E, Araz M, Bolek H, Kucuk NO, Urun Y. | Prostate. 2024. |
| Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG) | Yasar HA, Aktas BY, Ucar G, Goksu SS, Bilgetekin I, Cakar B, Sakin A, Ates O, Basoglu T, Arslan C, Demiray AG, Paydas S, Cicin I, Sendur MAN, Karadurmus N, Kosku H, Uner A, Yumuk PF, Utkan G, Kefeli U, Tanriverdi O, Cinkir H, Gumusay O, Turhal NS, Menekse S, Kut E, Beypinar I, Sakalar T, Demir H, Yekeduz E, Kilickap S, Erman M, Urun Y. | Clin Genitourin Cancer. 2024;22(3):102077. |
| Safety and efficacy of nivolumab therapy in patients with metastatic renal cell carcinoma and impaired kidney function | Sengul N, Gulturk I, Yilmaz M, Celik E, Paksoy N, Yekeduz E, Urun Y, Basaran M, Ozguroglu M. | Actas Urol Esp (Engl Ed). 2024;48(4):273-80. |
| Impact of low sodium values on survival outcomes of patients with cancer receiving immune checkpoint inhibitors | Karaoglan BB, Yekeduz E, Yazgan SC, Mocan EE, Koksoy EB, Yasar HA, Senler FC, Utkan G, Demirkazik A, Akbulut H, Urun Y. | Immunotherapy. 2024;16(12):821-8. |
| The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study | Almuradova E, Seyyar M, Arak H, Tamer F, Kefeli U, Koca S, Sen E, Telli TA, Karatas F, Gokmen I, Turhal NS, Sakalar T, Ayhan M, Ekinci F, Hafizoglu E, Kahraman S, Kesen O, Unal C, Alan O, Celik S, Yekeduz E, Omur O, Gokmen E. | Int J Cancer. 2024;154(4):692-700. |
| Impact of antihistamine use on the survival outcomes of immune checkpoint inhibitors in advanced cancer patients | Eylemer Mocan E, Yekeduz E, Karatas G, Yazgan SC, Koksoy EB, Cay Senler F, Utkan G, Demirkazik A, Akbulut H, Urun Y. | Anticancer Drugs. 2024;35(2):190-4. |
| External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by IMDC: Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database | Yekeduz E, Karakaya S, Erturk I, Tural D, Ucar G, Senturk Oztas N, Arikan R, Hizal M, Kucukarda A, Sever ON, Arslan C, Can O, Kilickap S, Yazgan C, Karadurmus N, Sendur MA, Cicin I, Demirci U, Ozguroglu M, Oksuzoglu B, Urun Y. | Clin Genitourin Cancer. 2023;21(1):175-82. |
| Visceral Metastasis Predicts Response to New Hormonal Agents in Metastatic Castration-Sensitive Prostate Cancer | Yekeduz E, McKay RR, Gillessen S, Choueiri TK, Urun Y. | Oncologist. 2023;28(7):596-603. |
| The effect of primary tumour resection on patients with synchronous metastatic colorectal cancer treated with cetuximab-containing regimens | Sertesen E, Yekeduz E, Koksoy EB, Urun Y, Erkek AB, Demirci S, Unal AE, Utkan G. | ANZ J Surg. 2023;93(4):945-50. |
| The benefit of treatment beyond progression with immune checkpoint inhibitors: a multi-center retrospective cohort study | Guven DC, Yekeduz E, Erul E, Yazgan SC, Sahin TK, Karatas G, Aksoy S, Erman M, Yalcin S, Urun Y, Kilickap S. | J Cancer Res Clin Oncol. 2023;149(7):3599-606. |
| Clinical Features and Prognostic Factors of Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multicenter Study from the Turkish Oncology Group Kidney Cancer Consortium | Erol C, Yekeduz E, Tural D, Karakaya S, Senturk Oztas N, Ucar G, Kilickap S, Erturk I, Sever ON, Arslan C, Kucukarda A, Can O, Balvan O, Yazgan SC, Ozguroglu M, Oksuzoglu B, Sendur MAN, Urun Y. | Urol Int. 2023;107(6):595-601. |
| Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study | Basoglu T, Sakin A, Erol C, Ozden E, Cabuk D, Cilbir E, Tataroglu Ozyukseler D, Ayhan M, Sendur MA, Dogan M, Oksuzoglu B, Eryilmaz MK, Er O, Tasci ES, Ozyurt N, Dulgar O, Ozen M, Hacibekiroglu I, Oner I, Bekmez ET, Cagri Yildirim H, Yalcin S, Paydas S, Yekeduz E, Aksoy A, Ozcelik M, Oyman A, Almuradova E, Karabulut B, Demir N, Dincer M, Ozdemir N, Erdem D, Ak N, Inal A, Salim DK, Deniz GI, Sakalar T, Gulmez A, Kacan T, Ozdemir O, Alan O, Unal C, Karakas Y, Turhal S, Yumuk PF. | J Chemother. 2023;35(2):142-9. |
| Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study | Bilici A, Koca S, Karaagac M, Aydin SG, Eraslan E, Kaplan MA, Ocak B, Goksu SS, Paydas S, Akgul F, Derin S, Ergun Y, Yekeduz E, Erol C, Ozyukseler DT, Demiray AG, Karaca M, Guc ZG, Menekse S, Cinkir HY, Gumusay O, Sakin A, Ozkul O, Demir H, Erdem D, Besiroglu M, Unal OU, Acar R, Koral L, Sahin S, Sakalar T, Bahceci A, Ozveren A, Gunaydin UM, Seker MM, Sunar V, Dal P, Artac M, Turhal S. | J Cancer Res Clin Oncol. 2023;149(11):8243-53. |
| Vortex keratopathy associated with ribociclib | Turkel A, Ozdogan S, Yekeduz E, Seyran E, Karacin C, Ates O. | J Oncol Pharm Pract. 2023;29(1):230-2. |
| The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study | Yekeduz E, Tural D, Erturk I, Karakaya S, Erol C, Ercelep O, Arslan C, Sever ON, Kilickap S, Senturk Oztas N, Kucukarda A, Can O, Oksuzoglu B, Sendur MA, Karadurmus N, Urun Y. | J Cancer Res Clin Oncol. 2022;148(12):3537-46. |
| Chronic hyperglycemia based on diabetes is independently associated with decreased survival in patients with advanced cancer treated with immune checkpoint inhibitors | Yekeduz E, Koksoy EB, Yazgan SC, Karatas G, Senler FC, Utkan G, Akbulut H, Demirkazik A, Urun Y. | Anticancer Drugs. 2022;33(10):1145-9. |
| Genomic Landscape of Actionable Mutations in Primary and Metastatic Tissues of Colon Adenocarcinoma | Yekeduz E, Akbulut H, Utkan G, Urun Y. | Cureus. 2022;14(4):e24175. |
| Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study | Yekeduz E, Ozbay MF, Caglayan D, Yildirim A, Erol C, Yildirim HC, Tunc S, Ozyurt N, Ozdemir F, Sendur MAN, Isikdogan A, Kilickap S, Urun Y, Yalcin S, Artac M, Coskun HS, Utkan G. | Eur J Clin Pharmacol. 2022;78(12):1973-9. |
| Key considerations and common adverse events for HIV-positive patients with cancer treated with immune checkpoint inhibitors | Yekeduz E, Utkan G, Urun Y. | Future Oncol. 2022;18(4):413-6. |
| Comparison of Clinical and Pathological Factors Affecting Early and Late Recurrences in Patients with Operable Breast Cancer | Yekeduz E, Dizdar O, Kertmen N, Aksoy S. | J Clin Med. 2022;11(9). |
| The prognostic role of polypharmacy in metastatic colorectal cancer patients treated with regorafenib | Yekeduz E, Aktas EG, Koksoy EB, Dogan N, Urun Y, Utkan G. | Future Oncol. 2022;18(9):1067-76. |
| Systemic Immune-Inflammation Index as a Prognostic Marker of Late Recurrence in Operable Gastric Cancer: a Dual-Center Study | Yekeduz E, Dogan I, Kaya DM, Ozgur I, Utkan G, Vatansever S, Demirci S, Akbulut H, Urun Y. | J Gastrointest Cancer. 2022;53(4):870-9. |
| The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors | Yucel KB, Yekeduz E, Karakaya S, Tural D, Erturk I, Erol C, Ercelep O, Oztas NS, Arslan C, Ucar G, Kucukarda A, Sever ON, Kilickap S, Can O, Yazgan SC, Oksuzoglu B, Karadurmus N, Sendur MA, Urun Y. | Sci Rep. 2022;12(1):16559. |
| Prognostic role of pan-immune-inflammation value in patients with metastatic castration-resistant prostate cancer treated with androgen receptor-signaling inhibitors | Yazgan SC, Yekeduz E, Utkan G, Urun Y. | Prostate. 2022;82(15):1456-61. |
| Assessing population diversity in phase III trials of cancer drugs supporting Food and Drug Administration approval in solid tumors | Yekeduz E, Trapani D, Xu W, de Vries EGE, Labaki C, Gyawali B, Gulati S, Nabhan C, Utkan G, Curigliano G, Choueiri TK, Urun Y. | Int J Cancer. 2021;149(7):1455-62. |
| mRNA-based COVID-19 vaccines appear not to increase immune events in cancer patients receiving immune checkpoint inhibitors | Yekeduz E, Ayasun R, Koksoy EB, Utkan G, Urun Y, Akbulut H. | Future Virol. 2021. |
| Commentary: Should all cancer patients be tested for COVID-19 before each chemotherapy cycle? | Yekeduz E, Utkan G, Urun Y. | J Oncol Pharm Pract. 2021;27(2):450-2. |
| Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database | Yekeduz E, Erturk I, Tural D, Karadurmus N, Karakaya S, Hizal M, Arikan R, Arslan C, Taban H, Kucukarda A, Oztas NS, Sever ON, Ucar G, Can O, Sendur MA, Demirci U, Kilickap S, Cicin I, Oksuzoglu B, Ozguroglu M, Urun Y. | Future Oncol. 2021;17(35):4861-9. |
| Adjuvant Treatment of Gastric Cancer in the D2 Dissection Era: A Real-life Experience from a Multicenter Retrospective Cohort Study | Yekeduz E, Dogan I, Birgi SD, Keskin M, Karaman S, Utkan G, Karabulut S, Bayar S, Akbulut H, Demirci S, Akyurek S, Urun Y. | Euroasian J Hepatogastroenterol. 2021;11(2):51-8. |
| ctDNA as a prognostic factor in operable colon cancer patients: a systematic review and meta-analysis | Yekeduz E, Koksoy EB, Akbulut H, Urun Y, Utkan G. | Future Oncol. 2021;17(3):349-57. |
| Expanding armamentarium in advanced prostate cancer management: are all novel antiandrogens the same? | Yekeduz E, Utkan G, Kanesvaran R, Urun Y. | Prostate Int. 2021;9(1):1-5. |
| In the Age of Immunotherapy, How Can We Translate the CARMENA Results into Practice? | Yekeduz E, Suer E, Utkan G, Baltaci S, Urun Y. | Eur Urol Oncol. 2021;4(3):515-6. |
| Neurotoxicities of novel non-steroidal anti-androgens for prostate cancer: A systematic review and meta-analysis | Bakouny Z, Yekeduz E, Braun DA, Berchuck JE, Hirsch L, Utkan G, Lee Y, Trinh QD, Choueiri TK, Urun Y. | Crit Rev Oncol Hematol. 2021;166:103463. |
| Response to letter entitled: Re: A systematic review and meta-analysis: The effect of active cancer treatment on severity of COVID-19 | Yekeduz E, Utkan G, Urun Y. | Eur J Cancer. 2021;152:248-9. |
| The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center study | Guven DC, Acar R, Yekeduz E, Bilgetekin I, Baytemur NK, Erol C, Ceylan F, Sendur MA, Demirci U, Urun Y, Karadurmus N, Erman M, Kilickap S. | Curr Probl Cancer. 2021;45(6):100760. |
| A clinical dilemma amid COVID-19 pandemic: missed or encountered diagnosis of cancer? | Yekeduz E, Karcioglu AM, Utkan G, Urun Y. | Future Oncol. 2020;16(25):1879-81. |
| Clinical course of COVID-19 infection in elderly patient with melanoma on nivolumab | Yekeduz E, Dursun B, Aydin GC, Yazgan SC, Ozturk HH, Azap A, Utkan G, Urun Y. | J Oncol Pharm Pract. 2020;26(5):1289-94. |
| A systematic review and meta-analysis: the effect of active cancer treatment on severity of COVID-19 | Yekeduz E, Utkan G, Urun Y. | Eur J Cancer. 2020;141:92-104. |
| A systematic review: Role of systemic therapy on treatment and prevention of brain metastasis in renal cell carcinoma | Yekeduz E, Arzu Yasar H, Utkan G, Urun Y. | J Oncol Pharm Pract. 2020;26(4):972-81. |
| Evaluation of cancer risk in patients with periodontal diseases | Guven DC, Dizdar O, Akman AC, Berker E, Yekeduz E, Ceylan F, Baspinar B, Akbiyik I, Aktas BY, Yuce D, Erman M, Hayran M. | Turk J Med Sci. 2019;49(3):826-31. |
| Seasonal Influenza And Pneumococcal Vaccination Rates Among Patients With Cancer In Covid-19 Pandemic: A Cross-Sectional Study | Yekedüz E, Köksoy EB, Yazgan SC, Akbiyik I, Balli S, Kavak EE, Kalaci E, Dursun B, Kubilay Tolunay P, Gürbüz M, Akbulut H, Demirkazik A, Çay Şenler F, Utkan G, Ürün Y. | Journal Of Oncological Sciences, 2021 |
| Efficacy Of Chemotherapy Combinations In Metastatic Castration-Resistant Prostate Cancer Patients – Do Homologous Recombination Deficiency Affect The Outcomes? | Yekedüz E, Utkan G, Ürün Y. | Bulletin of Urooncology, 2020 |
| Oncologic Approaches for Bone Metastasis Related Pain | Yekedüz E, Utkan G, Ürün Y. | Nuclear Medicine Seminars, 2020 |
| Docetaxel, Cisplatin, And Fluorouracil Combination Chemotherapy In Neoadjuvant Treatment Of Locally Advanced Esophageal Squamous Cell Carcinoma: A Retrospective Study | Ateş Ö, Yekedüz E, Kiliçkap S, Yalçin Ş. | Journal Of Oncological Sciences, 2020 |
| Unresectable Hepatocellular Carcinoma and Prognostic Factors of Sorafenib Treatment: A Real-Life Experience | Erol C, Bardakçi M, Hızal M, Kahraman S, Yekedüz E, Güven DC, Aykan MB, Ak R, Ateş Ö, Şener Dede D, Akinci MB, Karadurmuş N, Bal Ö, Ürün Y, Yalçin Ş, Yalçin B, Şendur MAN | J Oncol Sci. 2023 |
| Sorafenib In Radioactive Iodine Refractory Differentiated Thyroid Cancer: A Real-Life Data With Long-Term Experience | Yekedüz E, Köksoy EB, Çay Şenler F, Akbulut H, Demirkazik A, Ürün Y, Utkan G | Ankara Üniversitesi Tıp Fakültesi Mecmuası, 2022 |
| Predictive Factor for Lymph Node Metastasis in Non-Metastatic Colorectal Adenocarcinomas | Karci E, Urun Y, Koksoy E, Ucar G, Bilgin B, Yekeduz E, Arslan C. | EJMI. 2022 |
| An Unusual Cause Of Serum Ca-72-4 Elevation: Colchicine | Gürbüz M, Akkuş E, Kubilay Tolunay P, Karaalioğlu B, Yekedüz E, Karaoğlan M, Tutar DE, Utkan G | Case Reports Research Practices In Medicine, 2021 |
| Mortality Facts In Internal Medicine Wards: A Descriptive Study From University Hospital | Çalik Başaran N, Aktaş BY, Şener YZ, Ceylan S, Yekedüz E, Başpinar B, Şimşek C, Özişik L, Sain Güven G, Öz ŞG, Durusu Tanriöver M | Acta Medica, 2018 |
| Pneumococcal And Influenza Vaccination Coverage Rates Of Adult Patients At Risk And Their Attitudes Towards Vaccination | Özişik L, Yekedüz E, Durusu Tanriöver M, Helvaci Ö, Çalik Başaran N, Ünal S | Flora Infeksiyon Hastalıkları Ve Klinik Mikrobiyoloji Dergisi, 2016 |
| Germline determinants of pneumonitis in patients with cancer treated with antibody drug conjugates | Yekeduz E, Saad E, Machaalani M, Simsek B, Steiner C, Semaan K, Abdelnaser A, Eid M, Shavakhi M, Nawfal R, Chehade REH, Saliby RM, Khatoun WD, Saleh M, Tarantino P, McGregor BA, Bellmunt J, Tolaney SM, Gusev A, Choueiri TK. | Journal of Clinical Oncology 2025 (ASCO Annual Meeting) |
| Gut-associated checkpoint as a prognostic biomarker in metastatic renal cell carcinoma (mrcc): Results from a randomized first-line clinical trial | Saliby RM, Machaalani M, Zhong C, Silva CAC, Labaki C, Saad E, Steiner C, Yekeduz E, Eid M, Khatoun WD, Sun M, Cai T, Braun DA, Xu W, Derosa L, Lee G-SM, Xie W, Albiges L, Zitvogel L, Choueiri TK. | Journal of Clinical Oncology 2025 (ASCO Annual Meeting) |
| Comorbidity burden and effectiveness of immunotherapy in patients with metastatic renal cell carcinoma | Yekeduz E, Zarba M, Saad E, Wells C, Machaalani M, Chehade REH, Eid M, Labaki C, Nawfal R, Saliby RM, Semaan K, Steiner C, Heng DYC, Choueiri TK. | Journal of Clinical Oncology 2025 (ASCO GU) |
| Association of clinical characterization of renal cell carcinoma (rcc) with merlin protein deficiency and biallelic loss of NF2 | Yekeduz E, Machaalani M, Siegmund SE, Saad E, Chehade REH, Steiner C, Berg SA, McGregor BA, Mantia C, Ravi P, Xu W, Hirsch MS, Choueiri TK, Serzan MT. | Journal of Clinical Oncology 2025 (ASCO GU) |
| Genomic and proteomic predictors of sites of metastases in renal cell carcinoma | Steiner C, Saad E, Machaalani M, Saliby RM, Eid M, Semaan K, Yekeduz E, Ascione L, Horst JT, Lee J, Phillips N, Trowbridge R, Lee G-SM, Harel M, Dicker AP, McGregor BA, Braun DA, McKay RR, Choueiri TK, Xu W. | Journal of Clinical Oncology 2025 (ASCO Annual Meeting) |
| The impact of lymphocyte count dynamics on the predictive value of tumor mutational burden (tmb) for immune checkpoint inhibitors (ici) outcomes in patients (pts) with cancer | Saleh MJ, Saad E, Machaalani M, Chehade REH, Khatoun WD, Masri JE, Eid M, Nawfal R, Semaan K, Yekeduz E, Steiner C, Ascione L, Labaki C, Saliby RM, Zarif TE, Gusev A, Choueiri TK. | Journal of Clinical Oncology 2025 (ASCO Annual Meeting) |
| Association of IL-7 germline variants with immune-related adverse events (iraes) in cancer patients (pts) treated with immune checkpoint inhibitors (icis) | Saad E, An J, Mehrabad EM, Labaki C, Saliby RM, Semaan K, Eid M, Machaalani M, Chehade REH, Steiner C, Nawfal R, Yekeduz E, Shah PK, Asnani A, Sun M, Allen EMV, Choi JK, Park SR, Gusev A, Choueiri TK. | Journal of Clinical Oncology 2025 (ASCO Annual Meeting) |
| Baseline radiological tumor burden to sub-stratify imdc risk groups in metastatic renal cell carcinoma treated with first-line therapy: A post hoc analysis from a randomized phase iii trial | Nawfal R, Chehade REH, Semaan K, Eid M, Ascione L, Saad E, Khatoun WD, Saleh MJ, Masri JE, Xu W, Yekeduz E, Sun M, Braun DA, Gupta S, Heng DYC, Krajewski K, Choueiri TK. | Journal of Clinical Oncology 2025 (ASCO Annual Meeting) |
| Integrative clinical, genomic, and transcriptomic characterization of circulating kim-1 in metastatic rcc | Machaalani M, Saliby RM, Saad E, Steiner C, Zhong C, Yekeduz E, Liu X, Eid M, Chehade REH, Ascione L, Masri JE, Saleh MJ, Cai T, Sun M, Lee G-SM, Xie W, Signoretti S, McDermott DF, Choueiri TK, Xu W. | Journal of Clinical Oncology 2025 (ASCO Annual Meeting) |
| Landscape of genomic alterations in genes implicated in the regulation of hypoxia inducible factor (hif) signaling: A pooled analysis of two pan-cancer cohorts | Khatoun WD, Masri JE, Saad E, Eid M, Machaalani M, Saleh MJ, Nawfal R, Semaan K, Chehade REH, Steiner C, Yekeduz E, Ascione L, Labaki C, Saliby RM, Zarif TE, Signoretti S, McDermott DF, Allen EMV, Choueiri TK. | Journal of Clinical Oncology 2025 (ASCO Annual Meeting) |
| Refining intermediate-risk (ir) stratification in patients (pts) with metastatic renal cell carcinoma (mrcc) receiving first-line (1l) immunotherapy (io) within one year of diagnosis (dx) | Chehade REH, Nawfal R, Semaan K, Eid M, Saad E, Machaalani M, Yekeduz E, Steiner C, Khatoun WD, Maj D, Zarba M, Wells C, Pal SK, Suárez C, Takemura K, Li H, Baca SC, Xie W, Heng DYC, Choueiri TK. | Journal of Clinical Oncology 2025 (ASCO Annual Meeting) |
| Circulating kidney injury molecule-1 (kim-1) in association with kidney injury biomarkers and outcomes in metastatic renal cell carcinoma | Steiner C, Saad E, Saliby RM, Eid M, Semaan K, Machaalani M, Yekeduz E, Horst JT, Lee J, Phillips N, Trowbridge R, Pirovano M, Lima CSNH, Gupta S, Lee G-SM, Elon Y, Dicker AP, Bonventre J, Choueiri TK, Xu W. | Journal of Clinical Oncology 2025 (ASCO GU) |
| A comprehensive evaluation of gene expression-based signatures for detecting tertiary lymphoid structures (tls) in metastatic renal cell carcinoma (mrcc) | Saad E, Ahmar NE, Simsek B, Jegede O, Matar S, Mohanna RA, Yekeduz E, McDermott DF, Plimack ER, Sosman JA, Haas NB, Hurwitz ME, Hammers HJ, Allen EMV, Choueiri TK, Atkins MB, Signoretti S, Braun DA. | Journal of Clinical Oncology 2025 (ASCO GU) |
| Low versus low-intermediate risk metastatic renal cell carcinoma (mrcc): Contemporary data from the international mrcc database consortium (imdc) | Chehade REH, Xie W, Semaan K, Eid M, Machaalani M, Nawfal R, Saad E, Saliby RM, Steiner C, Yekeduz E, Wells C, Maj D, Zarba M, Pal SK, Suárez C, Takemura K, Basappa NS, Baca SC, Heng DYC, Choueiri TK. | Journal of Clinical Oncology 2025 (ASCO GU) |
| Enhancing outcomes in mcrpc: The impact of androgen receptor inhibitor sequencing before ¹⁷⁷lu-psma-617 therapy | Yazgan C, Kayaş K, Arslan C, Kapar C, Öztekin Ş, Ceylan F, Bolek H, Elboğa U, Ates O, Tural D, Kus T, Sendur MAN, Yekeduz E, Kucuk NO, Özdemir EÇ, Ürün Y. | Journal of Clinical Oncology 2025 (ASCO Epub) |
| A promising biomarker for papillary renal cell carcinoma: Sodium-Glucose cotransporter 2 gene expression (SGLT2) | Erman Akkus, Emre Yekedüz, Yüksel Ürün | 16th EMUC, 2024 |
| Applying genomic analysis to refine unclassified renal cell carcinoma | Emre Yekeduz, David A. Braun, Razane El Hajj Chehade, Marc Eid, Chris Labaki, Marc Machaalani, Amin Nassar, Rashad Nawfal, Eddy Saad, Renee Maria Saliby, Karl Semaan, Maxine Sun, Michelle S. Hirsch, Yüksel Ürün, Talal El Zarif, Toni K. Choueiri | ASCO Annual Meeting 2024 |
| ERBB2 mutations and association with molecular phenotype in urothelial carcinoma | Marc Machaalani, Talal El Zarif, Paul Stockhammer, Karl Semaan, Marc Eid, Razane El Hajj Chehade, Rashad Nawfal, Emre Yekeduz, Amin Nassar, Gwo-Shu Mary Lee, Sylvan C. Baca, Toni K. Choueiri, Michael J Grant, Joaquim Bellmunt | ASCO Annual Meeting 2024 |
| Impact of digital tools in oncology: A global analysis of the adoption of ONCOassist and NCCN Chemotherapy Order Templates | Maria Natalia Gandur-Quiroga, Martin Alejandro Krasnapolski, Emre Yekeduz, Matt Izzo, Kevin Dan Bambury, Gilberto Morgan | ASCO Annual Meeting 2024 (Epub) |
| Impact of β-adrenergic blockade on efficacy of immunotherapy in patients with metastatic clear cell renal cell carcinoma | Karl Semaan, Marc Eid, Eddy Saad, Wadih Issa, Renee Maria Saliby, Morgan Paul, Caiwei Zhong, Damla Gunenc, Noa Phillips, Rashad Nawfal, Marc Machaalani, Razane El Hajj Chehade, Emre Yekeduz, Chris Labaki, Talal El Zarif, Sylvan C. Baca, Wanling Xie, Bradley Alexander McGregor, Tian Zhang, Toni K. Choueiri | ASCO Annual Meeting 2024 (Epub) |
| ERBB2 amplifications across sex, race, and cancer types | M. Machaalani, R. El Hajj Chehade, A. Nassar, T. El Zarif, E. Saad, E. Yekeduz, R.M. Saliby, C. Steiner, R. Nawfal, K. Semaan, M. Eid, G-S.M. Lee, M. Pomerantz, R.R. McKay, P. Tarantino, D.A. Braun, M. Sun, S.M. Tolaney, T.K. Choueiri | ESMO Congress 2024 |
| Association between baseline radiological tumor burden (BRTB) and outcomes in metastatic clear cell renal cell carcinoma (mccRCC) | R. Nawfal, K. Semaan, M. Eid, M. Paul, R.M. Saliby, R. El Hajj Chehade, M. Machaalani, E. Saad, N. Phillips, J. Canniff, D. Vasseur, T. El Zarif, E. Yekeduz, M. Sun, S. Baca, D.A. Braun, W. Xie, K. Krajewski, T.K. Choueiri | ESMO Congress 2024 |
| Risk Factors of Immune Related Adverse Events in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors | Razane El Hajj Chehade, Karl Semaan, Renee Maria Saliby, Eddy Saad, Rashad Nawfal, Marc Machaalani, Marc Eid, Emre Yekeduz, Clara Steiner, Maxine Sun, Marina Kaymakcalan, Toni K Choueiri | Kidney Cancer Research Summit, 2024 |
| Prognostic role of metastatic site in patients with de novo metastatic prostate cancer: A population-based analysis in new hormonal agents era | Emre Yekeduz, Marc Eid, Eddy Saad, Renee Maria Saliby, Karl Semaan, Silke Gillessen, Toni K. Choueiri, Yuksel Urun | ESMO Congress 2023 (Poster Presentation) |